Manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs), split across three businesses. Domestic Formulations contributed 82% of FY26 sales and sells branded medicines in India, including antibiotics like Zifi, rehydration brand Electral and energy drink Enerzal, through prescriptions and over-the-counter channels. Export Formulations sells generic drugs in overseas markets, primarily the United States, and received US FDA approvals for Fluconazole Tablets and Cefixime for Oral Suspension USP during FY26. The API business manufactures and sells bulk drug ingredients to other pharmaceutical companies. FY26 consolidated revenue was Rs. 2,171 crore with EBITDA margin of 20.2%, and the Q4 FY26 quarter alone brought in Rs. 585 crore at 18.9% year-on-year growth, led by exports. Operating costs are dominated by materials (26.5% of revenue), employee costs (22.2%) and other operating expenses (29.1%), with depreciation at 2.7% and capex at 8.6% of revenue. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Domestic Formulations (82%), Export Formulations, API (Active Pharmaceutical Ingredients). Branded and generic pharmaceutical formulations manufacturer with regulated US export exposure.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,528 | 1,784 | 1,943 | 2,108 | 2,171 |
| EBITDA (ex other income) | 254 | 251 | 339 | 325 | 325 |
| margin % | 16.6 | 14.1 | 17.4 | 15.4 | 15.0 |
| Owners' profit | 7 | 194 | 305 | 267 | 281 |
| EPS, as reported (₹) | 12.81 | 11.66 | 18.58 | 16.39 | 17.29 |
| ROE % · ROCE % | 11.0 · 14.6 | 9.8 · 12.9 | 14.5 · 18.6 | 11.7 · 15.4 | 11.3 · 14.9 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 162 | 155 | 221 | 318 | 200 |
| Capex | (133) | (113) | (93) | (97) | (187) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 514 | 464 | 492 | 648 | 473 | 465 | 585 | 668 |
| Profit before tax | 90 | 51 | 53 | 160 | 38 | 36 | 140 | 175 |
| Net profit | 72 | 37 | 39 | 121 | 28 | 28 | 103 | 132 |
| EPS (₹) | 4.43 | 2.28 | 2.38 | 7.45 | 1.75 | 1.74 | 6.35 | 8.14 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 4 Sept 2026 · Notice of 86th AGM published in newspapers; AGM on Sep 24, 2026 | compliance | minimal | — | — |
| 3 Sept 2026 · FDC promoter Nandan Chandavarkar transfers 3.09% stake to family trusts | ownership changes | medium | — | — |
| 1 Sept 2026 · FDC Limited submits BRSR for FY 2025-26 to exchanges | compliance | minimal | — | — |
| 1 Sept 2026 · FDC Limited 86th AGM on Sep 24, 2026; share transfer books closed Sep 17-23 | board shareholder meetings | low | — | — |
| 1 Sept 2026 · FDC Limited Annual Report FY26, AGM on Sept 24, 2026 | results | high | — | — |
| 1 Sept 2026 · FDC 86th AGM Notice on September 24, 2026 via Video Conferencing | board shareholder meetings | low | — | — |
| 1 Sept 2026 · FDC 86th AGM notice published; September 24 meeting via video conferencing | compliance | minimal | — | — |
| 27 Aug 2026 · Delhi HC grants interim stay on FSSAI notice on electrolyte drink labels | regulatory legal | high | — | — |
| 13 Aug 2026 · FDC subsidiary gets UK MHRA approval for Atropine eye drops | business updates | medium | — | — |
| 5 Aug 2026 · FDC Q1 FY27: PAT up 9% at Rs 132 cr, US business surges 118% | compliance | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 19.0 | 28.9 | 54 of 169 | 69% |
| P/B | 2.2 | 3.3 | 55 of 163 | 67% |
| ROCE | 14.7 | 10.8 | 69 of 183 | 63% |
| ROE | 11.3 | 10.4 | 79 of 171 | 54% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 28.6 | 17.5 | 40 of 165 | 76% |
| Revenue growth | 3.0 | 16.3 | 119 of 161 | 26% |
| Profit growth | 9.2 | 30.9 | 102 of 158 | 36% |
| Market cap | 5568 | 839 | 58 of 182 | 69% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
